Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a two-phase study. Phase 1 will evaluate obesity-related behavioral and biological
characteristics as potential predictors of response to behavioral treatment (BT) for weight
loss. Phase 2 is a double-blind, placebo-controlled, RCT to test whether adding weight loss
medication to BT improves 24-week weight loss, as compared to BT with placebo, in subjects
identified as having suboptimal early weight loss after 4 weeks of individual behavioral
weight control. All participants, regardless of their early weight loss, will receive the
same BT program of diet, physical activity, and behavior therapy for weight loss for an
additional 24 weeks (28 total weeks of treatment).
Phase:
Phase 4
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)